Global Migraine Therapeutics Market Size study & Forecast, by Therapeutics (Pain-relieving Medications, Preventive Medications), by Route of Administration (Oral & Nasal, Injectables), and Regional Analysis, 2022-2029

Global Migraine Therapeutics Market Size study & Forecast, by Therapeutics (Pain-relieving Medications, Preventive Medications), by Route of Administration (Oral & Nasal, Injectables), and Regional Analysis, 2022-2029

Global Migraine Therapeutics Market is valued at approximately USD XX billion in 2021 and is anticipated to grow with a healthy growth rate of more than XX% over the forecast period 2022-2029.A crippling neurological condition called migraine is characterised by frequent occurrences of excruciatingly painful, throbbing headaches that can last up to three days. These headaches, which are typically unilateral, can last anywhere between four hours and three days. Pain is frequently accompanied by additional symptoms such perspiration, diarrhoea, tingling or numbness in the legs or extremities, nausea, vomiting, increased sensitivity to sound (phonophobia), increased sensitivity to light (photophobia), and vomiting.. To treat migraine, migraine therapeutics are being used. The Migraine Therapeutics market is expanding because of factors such as growing awareness about Migraine and its treatment options and increasing prevalence of Migraines along with high unmet needs. However, adverse effects of drugs and lack of proper diagnosis and increasing undiagnosed cases may halt market growth.

The American Food and Drug Administration (FDA) approved Lundbeck's VYEPTI (eptinezumab-jjmr) in February 2020 for the adult population's migraine prevention. Additionally, in May 2021, the United States Food and Drug Administration (FDA) approved Biohaven Pharmaceutical Holding Company Ltd.'s NURTEC ODT (rimegepant 75 mg) for the treatment of migraines before they start. Adult patients with episodic migraine, such as those who encounter fewer than 15 headache days per month, are advised to use NURTEC ODT. Over the projected term, these approvals drive the study market's expansion. In addition, AbbVie reported favourable results from a phase 3 clinical trial testing atogepant (marketed as QULIPTA in the US) for the prevention of chronic migraine in adults in March 2022. It is an antagonist of the CGRP receptor that is taken orally (gepant). For both the 60 mg once daily (QD) and the 30 mg twice daily (BID) doses, the medication achieved the trial's primary aim of a statistically significant reduction from baseline in mean monthly migraine days compared to placebo over the course of the 12-week treatment period. The successful launch of this Therapeutics may provide patients with an alternative option.

The key regions considered for the Global Migraine Therapeutics Market study include Asia Pacific, North America, Europe, Latin America, and Rest of the World.Due to the dominance of branded Therapeutics and the rising prevalence of diseases in the region, North America dominated the space in terms of revenue. In 2020, there will be approximately 37.3 million diabetics in the United States, including 28.7 million instances that have been diagnosed and 8.5 million cases that have not. Due to factors like growing geriatric and target populations, an increase in the number of collaborations for biosimilar development, geographic expansion of key players, and active involvement of the government and nonprofit organisations in the market space, Asia Pacific is predicted to experience significant growth during the forecast period..

Major market players included in this report are:
Amgen
Abbvie Inc.
AstraZeneca
Eli Lilly and Co.
GlaxoSmithKline
Merck & Co., Inc.
Pfizer
Bausch Health
Teva Pharmac
Novartis AGeuticals

Recent Developments in the Market:
 In February 2022, the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) recently approved Rimegepant, a calcitonin gene-related peptide (CGRP) receptor antagonist, from Biohaven Pharmaceutical Holding Company Ltd. and Pfizer Inc. The oral dissolving tablet form of Rimegepant, which comes at a dose of 75 mg, is advised for use in the prevention of episodic migraine in adults who experience at least four migraine attacks per month as well as in the acute treatment of migraine with or without aura in adults.
 In Aug 2022, The U.S. Food and Drug Administration (FDA) approved an expanded label for Eli Lilly and Company's rapid-acting Migraine Therapeutics, Lyumjev® (Migraine Therapeutics lispro-AABC injection) 100 units/mL indicated to improve glycemic control in adults with type 1 and type 2 diabetes, to include administration via continuous subcutaneous Migraine Therapeutics infusion (CSII) with a Migraine Therapeutics pump.
 In July 2021, BioDelivery Sciences announced the introduction of new drug, Elyxyb.It is one of the first adult ready-to-use oral solutions for the acute treatment of migraine, with or without aura, that the Food and Drug Administration has approved.

Global Migraine Therapeutics Market Report Scope:
Historical Data 2019-2020-2021
Base Year for Estimation 2021
Forecast period 2022-2029
Report Coverage Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered Therapeutics, Route of Administration, Region
Regional Scope North America; Europe; Asia Pacific; Latin America; Rest of the World

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and Therapeutics offerings of key players.

The detailed segments and sub-segment of the market are explained below:
By Therapeutics:
Pain-relieving Medications
Preventive Medications

By Route of Administration:
Oral & Nasal
Injectables

By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World

Companies Mentioned

Amgen
Abbvie Inc.
AstraZeneca
Eli Lilly and Co.
GlaxoSmithKline
Merck & Co., Inc.
Pfizer
Bausch Health
Teva Pharmac
Novartis AGeuticals

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.